<DOC>
	<DOCNO>NCT02465606</DOCNO>
	<brief_summary>The primary objective study evaluate safety lebrikizumab compare Topical Corticosteroids ( TCS ) alone patient persistent moderate severe Atopic Dermatitis ( AD ) inadequately control TCS .</brief_summary>
	<brief_title>A Study Evaluate Safety Lebrikizumab Compared Topical Corticosteroids Adult Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age 18 75 year , inclusive , start runin period AD diagnose Hanifin/Rajka criterion present least 1 year screen Moderate severe AD grade Rajka/Langeland criterion screen History inadequate response &gt; /= 1 month ( within 3 month prior screen visit ) treatment regimen least daily TCS regular emollient treatment AD EASI score &gt; /= 14 screen IGA score &gt; /= 3 AD involvement &gt; /= 10 % body surface area Pruritus Visual Analog Scale score &gt; /= 3 Past and/or current use antiIL13 antiIL4/IL13 therapy , include lebrikizumab Use investigational agent within 4 week prior screen within 5 halflives investigational agent , whichever long Evidence skin condition , include , limited , Tcell lymphoma allergic contact dermatitis History severe allergic reaction anaphylactic reaction biologic agent know hypersensitivity component lebrikizumab injection Use complementary , alternative , homeopathic medicine include , limited , phytotherapy , traditional nontraditional herbal medication , essential fatty acid , acupuncture within 7 day prior runin period need medication study Evidence skin condition ; include , limited , Tcell lymphoma allergic contact dermatitis Evidence , ongoing treatment ( include topical antibiotic ) active skin infection screen Other recent infection meet protocol criterion Active tuberculosis require treatment within 12 month prior Visit 1 Evidence acute chronic hepatitis know liver cirrhosis Known immunodeficiency , include HIV infection Use topical calcineurin inhibitor ( TCI ) time screen , unless patient willing stop TCI use study ( include runin period ) , investigator 's opinion , safe Clinically significant abnormality screen ECG laboratory test Known current malignancy current evaluation potential malignancy , include basal squamous cell carcinoma skin carcinoma situ History malignancy within 5 year prior screen , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage I uterine cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>